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Mycosis fungoides (MF) is typically an indolent disease except when large cell transformation (LCT)
occurs. The incidence of LCT has been reported to range from 6% to 23% under the criterion of the
presence of more than 25% of large cells in a biopsy of typical MF lesions. LCT is more common in
advanced-stage MF, but very rarely found in its early stage. Herein, we present a 45-year-old womanwith
patch stage MF (Stage IB) who developed a papule within one patch, which revealed large cell trans-
formation with expression of CD30 immunostaining on histopathology. The patient then received
phototherapy with narrow-band UVB. The skin lesions regressed quickly and no new skin lesions had
been noted during the 6-month follow-up. Intense monitoring for recurrence and extracutaneous
involvement is still recommended. In this article, we also review the published articles of mycosis
fungoides with CD 30-positive large cell transformation and analyze the clinicopathological and prog-
nostic features.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Mycosis fungoides (MF) comprises about 65% of cutaneous T-cell
lymphomas.1 It generally presents with an indolent course and
a long evolution, with years to decades elapsing before patches or
plaques progress to tumor stage. Large cell transformation (LCT) in
MF has been deﬁned by the presence of large cells (at least four
times larger than a small lymphocyte) exceeding 25% of the total
lymphoid inﬁltrate or forming microscopic nodules.2 LCT is often
found in advanced-stage disease (Stage IIB) and is very rare in the
early stage (Stage IIA).3 LCT in MF is associated with an aggressive
course and poor prognosis.3 Large transformed cells may be posi-
tive for CD30 or not.4 Herein, we reported a patient with Stage IB
MF, who also showed focal CD30-positive LCT.
Case report
This 45-year-old woman, without major systemic diseases, pre-
sented with multiple asymptomatic reddish rashes over the left
forearm, left ﬂank, buttocks, and thighs for 10 years. The rash ﬁrstlogy, Chung Shan Medical
North Road, Taichung 402,
6 4 23248116.
y).
iwanese Dermatological Associatioappeared on the left forearm and slowly extended to the left ﬂank,
buttocks, and thighs. She had visited a local practitioner’s clinic
where she was diagnosed with eczema, but did not respond to
treatment. Approximately one year earlier, one reddish papule
arose from the reddish patch over her left ﬂank and showed no
regression.
Skin examination revealed multiple asymptomatic, scaly,
wrinkling, mottled reddish and hypopigmented patches over the
left forearm, left ﬂank, both buttocks and thighs (Figure 1A, B and
C). About 15% of the total body surface area was involved. Addi-
tionally, one reddish papule located within reddish patches over
the left ﬂank was also noted (Figure 1B). Review of the patient’s
history over the previous 10 years indicated absence of fever, chills,
or body weight loss. There were no palpable lymph nodes or
hepatomegaly. Results of a complete blood count, liver function,
and lactate dehydrogenase were within normal limits. The
peripheral blood did not show atypical lymphocytes. Chest x-ray
revealed no signiﬁcant ﬁndings. Total body positron emission
tomography indicated no abnormal uptake in visceral organs.
Histopathology of a biopsy specimen from a reddish patch over
the left ﬂank demonstrated mild inﬁltration of atypical cerebriform
lymphocytes at the dermal-epidermal junction with focal epi-
dermotropism (Figure 2A and B). The cells were positively stained
with CD3, CD4, and CD8, but negative for CD20 and CD30
(Figure 2CeF). Another skin biopsy was taken from the reddishn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 (A, B and C) Multiple asymptomatic, mottled reddish and hypopigmented patches with wrinkled surface and scales over the left forearm, left ﬂank, left back, buttocks, and
thighs. One reddish papule located within a reddish patch over the left ﬂank (arrow).
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showed diffuse intradermal lymphocytic inﬁltration with large
pleomorphic and hyperchromatic lymphocytes (Figure 3AeC). The
cells were positively stained with CD3 and CD4, and focally with
CD8 (Figure 3D and E), but negative for CD20. Of all inﬁltrating
atypical lymphocytes, about 60% were large cells. They were
strongly positive for CD30 (more than 75% of large cells) (Figure 3F),
but negative for anaplastic lymphoma kinase and CD68. Poly-
merase chain reaction of skin biopsy from the reddish patch over
the left ﬂank showed clonality of the T-cell receptor g gene
rearrangement.
Based on the clinical manifestation and histopathological ﬁnd-
ings, the patient was diagnosed with MF with focal CD30-positive
LCT. The staging of disease was T2N0M0, Stage IB. The patient
then received topical steroid and narrow-band UVB phototherapy.
Her skin lesions regressed quickly and no new lesions were noted at
the 6-month follow-up.
Discussion
Mycosis fungoides (MF) is the most common type of cutaneous
T-cell lymphomas.1 Generally, the clinical manifestation shows
three phases- patch, plaque and tumor stage, and typically runs an
indolent course with a long evolution over years to decades.5
However, with disease progression, a small number of cases
develop a morphologic change (large cell transformation), espe-
cially more common in the advanced stage of disease. The diagnosis
of large cell transformation (LCT) in MF always relies on histologi-
cally deﬁned criterion: the presence of large cells exceeding 25% ofthe total lymphoid inﬁltrate or forming microscopic nodules.2
Mycosis fungoides with LCT usually portends an aggressive
course and shortened survival.2 Diamandidou et al3 reported
shorter median survival for patients with LCT in MF (37 months),
compared with nontransformed MF (163 months). Arulogun et al4
also indicated a lower 5-year survival rate for LCT group than
nontransformed group of MF patients, 32.5% versus 53.6%.4
Although the molecular mechanism for LCT has not been fully
demonstrated, molecular studies have conﬁrmed that large cells
are derived from the original T-cell clone in MF. 6,7 Around 30% to
50% of MF patients with LCT showed CD30-positive cells.4,8,9
Although the histological criterion for the diagnosis of LCT in MF
has been well deﬁned, making a deﬁnite differential diagnosis is
still sometimes challenging. MF with focal CD30-positive LCT
should be differentiated from other CD30 positive lymphoproli-
ferative disorders, including primary cutaneous anaplastic large cell
lymphoma, lymphomatoid papulosis (LyP), and borderline cases.
1Primary cutaneous CD30þ lymphoproliferative disorders typically
have an excellent prognosis with a disease speciﬁc 5-year survival
of 85% to 100%.10,11 However, CD30 positive LCT in MF has worse
outcomewith a 5-year survival of 28.6% to 44.4%.4,8 Meanwhile, the
clinical manifestations are obviously different between CD30
positive LCT in MF and primary cutaneous CD30 positive lympho-
proliferative disorders. Coexisting MF and LyP is found in 9% of
patients with LyP, and represents 3% of MF patients.10 Many studies
show MF with concurrent LyP leads an indolent course and has
a favorable prognosis.12e15 The clinical course of LyP with concur-
rent MF is also similar to that of LyP, and the skin lesions tend to
regress spontaneously and then recur. By contrast, CD30þ LCT in
Figure 2 (A) Histopathology of a biopsy specimen from a reddish patch over the left ﬂank reveals mild inﬁltration of atypical lymphocytes over the dermal-epidermal junction and
upper dermis [hematoxylin and eosin (HE, 200)]. (B) Focal epidermotropismwith inﬁltration of atypical, cerebriform lymphocytes, each surrounded by a clear halo (HE, 400). (C)
Immunohistochemical staining reveals the inﬁltrating lymphocytes to be CD3 positive (400). (D) Positive staining for CD4 (400). (E) Positive staining for CD8 (400). (F) Negative
staining for CD30 (400).
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from normal skin and/or previous MF lesions, while CD30þ LCT
always develops upon pre-existent MF lesions. The coexistence of
MF and CD30-positive anaplastic large cell lymphoma (ALCL) has
also been reported previously, but, as shown in these cases, the two
diseases invariably appear in separate locations and run indepen-
dent clinical course.16,17 The diagnosis of CD30 positive LCT in MF
should be madewhen newly-onset papules or nodules arising from
the prior MF lesions are seen clinically, and cerebriform T
lymphocytes admixing with <75% of CD30 positive large cells are
shown histopathologically.2,8 If >75% of large cells have CD30
expression, it is very difﬁcult to distinguish CD30þ LCT in MF from
MF associated with CD 30þ lymphoproliferative disorder. In such
a situation, Vergier et al indicated the clinical evolutionmay help us
discriminate between these two entities.8
Applying this to our patient, we observed one reddish papule
developing upon the previous typical MF lesion (clinical evolution),
which hadnot shownspontaneous remission for oneyear. Dissimilar
to LyP, which typically manifests chronic recurrent self-healing
papules and nodules that inevitably regress, the clinical course of
the reddishpapule in our patient showedno spontaneous necrosis orregression. The microscopic examination of a biopsy specimen from
the reddish papule in our case revealed inﬁltration of mononuclear
cells mixed with large atypical cells in the upper dermis, and focal
epidermotropism of atypical mononuclear cells in the epidermis.
There were hardly any neutrophils or eosinophils within the intra-
dermal mononuclear inﬁltrate. Around 60% of the lymphocytic
inﬁltrates were large pleomorphic and hyperchromatic, with about
90%of those large cells beingCD30þ. Compared toALCL, inwhich the
tumor cells commonly extend into the subcutaneous fat or deeper
tissues, or LyP, the inﬁltrate of which often contains large anaplastic
cells mixedwith neutrophils, eosinophils, plasma cells, lymphocytes
and histiocytes, the histopathologic ﬁndings of the present case do
not match any type of LyP and were not compatible with ALCL. The
combination of histological ﬁndings and clinical evolution leads to
the diagnosis of early stage MF (Stage IB) with focal CD30-positive
large cell transformation.
Reviewing the literature, treatments for LCT in MF were
heterogeneous and dependent on the clinical stage.3,8,9,18,19 For
patients with early stage MF, skin-directed therapy including
topical corticosteroids, topical nitrogen mustard, light therapy and
radiation therapy had been used.9,18,19 One patient presenting with
Figure 3 (A) Microscopic examination of a biopsy specimen from the reddish papule reveals dense inﬁltration of mononuclear cells in the upper dermis and perivascular area (HE,
40). (B) Inﬁltration of mononuclear cells mixed with large atypical cells in the upper dermis, and focal epidermotropism with atypical mononuclear cells in the epidermis (HE,
200). (C) Large atypical pleomorphic cells with vesicular nuclei and prominent nucleoli (HE, 400). (D) Large atypical cells are stained with CD4 (400). (E) Large atypical cells are
weakly positive for CD8 (400) and (F) strongly positive for CD30 (400).
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topical nitrogen mustard, and the lesions almost totally resolved
after 2 to 3 months of therapy. 18 Another patient who was diag-
nosed with LCT in MF (Stage IIB) received electron beam radiation,
and no local recurrence or distant metastasis has been noted for
1 year.18 In our case, the reddish papule was surgically removed
ﬁrst. For residual skin lesions, we suggested PUVA, the ﬁrst-line
treatment for early stage MF, which our patient declined because
of its carcinogenic potential. Local radiation was not suitable for
multiple skin lesions. Therefore, we administered narrow band UVB
phototherapy, which is also effective in management of early stageTable 1 Comparisons of previous studies reporting the incidence of large cell transform
Salhany et al2 Greer et al22
No. of mycosis fungoides 92 113
No. of LCTs 17 22
No. of CD30-positive LCTs 4 NA
No. of LCTs in early-stage MF 6 7
No. of CD30-positive LCTs in early-stage MF 1 NA
NA ¼ not available.MF,20,21 and her skin lesions regressed quickly with no new skin
lesions noted at the 6-month follow-up.
According to the previously published articles, several prog-
nostic factors of large cell transformation in MF have been
mentioned. Diamandidous et al3 reported early transformation (<2
years from the diagnosis of MF) and more advanced disease at
transformation (Stage IIBeIV vs. Stage IeIIA) were associated with
a poor outcome, while an older age (60 years) and the presence or
extracutaneous spreading (Stage IV) were related with a poor
prognosis as indicated by Vergier et al.8 Although median survival
for patients with LCT in MF is markedly shortened, CD30þ large cellation (LCT) in mycosis fungoides (MF).
Diamadidou et al3 Vergier et al8 Barberio et al9 Arulogun et al4
115 419 208 358
26 45 17 22
NA 14 9 9
7 2 7 3
NA 0 5 NA
Table 2 Clinical and immunohistochemical data of patients with large cell trans-
formation (LCT) in early-stage mycosis fungoides (MF).
Patient No. Age/sex Stage at
LCT-MF
Interval from dx of
MF to LCT-MF (months)
CD30
expression
12 34/M IA 0 NA
22 76/M IIA 14 P
32 72/M IA 0 NA
42 55/M IIA 72 NA
52 67/M IA 48 NA
62 76/F IB 46 N
722 34/M IA 0 NA
822 76/M IIA 14 NA
922 72/M IA 0 NA
1022 55/M IIA 72 NA
1122 67/M IA 48 NA
1222 76/F IB 46 NA
1322 85/F IIA 36 NA
1422 56/NA IB 1 NA
153 71/NA IIA 0 NA
163 69/NA IB 75 NA
173 51/NA IB 75 NA
183 33/NA IIA 5 NA
193 78/NA IB 0 NA
203 60/NA IIA 7 NA
218 77/F IB 18 years N
228 68/F IB 48 N
239 50/M IA 1 P
249 78/F IA 84 P
259 55/M IB 5 P
269 77/M IA 84 N
279 54/F IA 6 N
289 52/M IIA 0 P
299 62/M IIA 72 P
3018 16/F IB NA P
3119 65/F IA 9 years NA
32 (present case) 45/F IB 0 P
F ¼ female; M ¼ male; N ¼ negative; NA ¼ not available; P ¼ positive.
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Vergier et al.8 ﬁrst analyzed CD 30 expression for its prognostic
value. Although there was no signiﬁcant difference, the 5-year
survival rates for patient groups with CD30- LCT, CD30þ <75%
LCT and CD30þ 75% LCT were 14.1%, 28.6% and 44.4%, respec-
tively. Arulogun et al4 also observed a tendency toward a better
outcome for MF patients with CD30þ LCT than those with CD30e
LCT. Moreover, Barberio et al9 stated that the strong positivity of
CD30 immunostaining of LCT inMFwas linked to a better prognosis
and indicated that CD30e LCT with a CD20þ B-cell peritumoral
inﬁltrate could be considered as a poor prognostic factor.9
LCT in MF is uncommon in nature. Previous studies reporting
the incidence of LCT in MF are summarized in Table 12e4,8,9,22.
However, LCT often occurs in advanced stage of MF, especially in
stage IIB and the tumor stage (T3).3 Early stage MF with large cell
transformation is very rare, and the incidence has been reported to
be between 0.5% and 7%. To the best of our knowledge, there have
been 31 cases of LCT in early stage MF previously reported in the
English literature (Table 2)2,3,8,9,18,19,22. Among these patients, fewer
than 10 expressed CD30 positivity, for whom the prognosis was
relatively good.2e4,8,9,18,19
In conclusion, we present a patient with early stage MF (Stage
IB) and LCT that showed strong expression of CD30. Although LCT in
MF usually indicates a more aggressive course and shortened
survival, its occurrence in an early stage and CD30 expression75%
both suggest a better prognosis among them. Besides, differentia-
tion between CD30þ LCT in MF and MF associated with a CD30
positive lymphoproliferative disorder should be made carefully
because of the divergence in their prognoses. To establish a precisediagnosis, we should pay special attention to both clinical and
histologic ﬁndings. Close observation and systemic surveys are also
essential to the evaluation of MF patients. When clinical evolution
with changing skin lesion occurs, we need to perform skin biopsy
and systemic evaluation to determine the disease status. Thorough
explanation to the patient about the disease prognosis and the
necessity of regular follow-ups should also be emphasized.References
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